Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O. Tandstad T, et al. Among authors: stierner u. Ann Oncol. 2010 Sep;21(9):1858-1863. doi: 10.1093/annonc/mdq026. Epub 2010 Feb 8. Ann Oncol. 2010. PMID: 20142410 Free article. Clinical Trial.
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.
Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G; SWENOTECA. Tandstad T, et al. Among authors: stierner u. Ann Oncol. 2014 Nov;25(11):2167-2172. doi: 10.1093/annonc/mdu375. Epub 2014 Aug 11. Ann Oncol. 2014. PMID: 25114021 Free article.
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).
Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G; SWENOTECA. Tandstad T, et al. Among authors: stierner u. Ann Oncol. 2016 Jul;27(7):1299-304. doi: 10.1093/annonc/mdw164. Epub 2016 Apr 6. Ann Oncol. 2016. PMID: 27052649 Free article.
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.
Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E. Olofsson SE, et al. Among authors: stierner u. J Clin Oncol. 2011 May 20;29(15):2032-9. doi: 10.1200/JCO.2010.29.1278. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21482994 Clinical Trial.
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register.
Lyth J, Hansson J, Ingvar C, Månsson-Brahme E, Naredi P, Stierner U, Wagenius G, Lindholm C; Swedish Melanoma Study Group. Lyth J, et al. Among authors: stierner u. Br J Dermatol. 2013 Apr;168(4):779-86. doi: 10.1111/bjd.12095. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23066913 Free article.
Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
Eriksson H, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, Naredi P, Stierner U, Wagenius G, Carstensen J, Hansson J. Eriksson H, et al. Among authors: stierner u. Eur J Cancer. 2013 Aug;49(12):2705-16. doi: 10.1016/j.ejca.2013.03.013. Epub 2013 Apr 11. Eur J Cancer. 2013. PMID: 23583439
69 results